MARLBOROUGH, Mass. -- (BUSINESS WIRE) -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure® V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17). The most studied and trusted endometrial ablation procedure in the United States, the innovative new NovaSure® V5 device represents Hologic's ongoing commitment to enhance the physician experience.1

Over the last 20 years, the NovaSure system has built a trusted legacy in GEA. The NovaSure device first received FDA approval in 2001, and by 2018 the NovaSure procedure had been used to treat over 3 million patients.2

"The NovaSure V5 device is at the forefront of innovation, established on an unmatched 20-year history of success and updated based on customer feedback," says Essex Mitchell, Division President GYN Surgical Solutions, Hologic. "By listening to physicians and using their feedback as a guide for new innovation, Hologic's GYN Surgical Solutions division remains committed to putting physicians and the women they serve first. We are always striving to work in partnership with physicians to achieve better outcomes for women."

Guided by women's unique needs and the physicians that treat them, the NovaSure V5 device features several innovations, making it the most sophisticated device in the NovaSure family. The device has an updated cervical seal, featuring EndoForm™ technology, designed to increase the sealing surface and accommodate a range of cervical canals and anatomical variability.3,4,5 The device's AccuSheath™ markings are designed to improve the accuracy and confidence of seating and fundal placement.6 Additionally, the NovaSure V5 device is equipped with SureClear™ technology, Hologic's unique fluid removal system, which provides integrated suction through the array by constant tissue contact while simultaneously removing ablation byproducts such as vapor and fluid from the uterus.7

"I have used NovaSure for 20 years and consider it the gold standard treatment for patients with menstrual disorders. Believing there was no needed room for improvement, the V5 enhanced cervical seal feature has exceeded my expectations," says Dr. Kelli Miller, MD, the first physician to perform the GEA procedure with the new NovaSure V5 device. "The markings added to the sheath correspond with the uterine sound measurement, further reassuring me of accurate placement. Ultimately, every woman has unique anatomy, and the cervical seal contours to a range of cervical canals, providing an advanced treatment option. Best of all, the V5 device does not require a steep learning curve, allowing the improvements to be even more appreciated by the physician."

The NovaSure V5 endometrial ablation system is not only outfitted to support the physician through comfort and control but is also specifically designed to cater to various cervical canal sizes, staying true to Hologic's promise of keeping the patient in the forefront of every decision.3

Learn more about the advancements made to the innovative NovaSure V5 device and the impact these changes will have on physician experience at the AAGL hybrid conference. The NovaSure V5 device will be on display at the Hologic booth #536 and online at Hologic's virtual surgery suite


About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Endoscopy Homepage